P.3.b.028 - Gene polymorphism of neurotransmitter transporters in schizophrenic patients with drug-induced hyperprolactinemia

Abstract

The regular therapy of schizophrenia includes a maintenance antipsychotic treatment, which improves the long-term prognosis of the disease [2]. Unfortunately antipsychotics also have a spectrum of side effects, including metabolic, endocrine and movement disorders [3,4]. One of the common side effects of these drugs is hyperprolactinemia (HP) [1]. The results of pharmacogenetic studies aimed at prognostic evaluation of the safe use of antipsychotics are the most persuasive. The components of dopamine, serotonin and norepinephrine neurotransmission in schizophrenia are considered as the main target for the action of antipsychotics. The present study aims to elucidate the role of 12 SNPs of dopamine transporter gene SLC6A3, 9 SNPs of norepinephrine transporter gene SLC6A2 and polymorphism of vesicular monoamine transporter gene SLC6A2 in the pathogenesis of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. A total of 445 ethnic Russian patients from Siberia regions were studied, including 224 women and 221 men with a diagnosis of paranoid schizophrenia (the mean age - 42.1±1.4 years). Prolactin level was analyzed using the AccuBind ELISA Microwells kit (Monobind Inc., USA). Genotyping of SNPs was done with The MassARRAY® Analyzer 4 by Agena Bioscience™, using SEQUENOM. Statistical analysis was performed using the SPSS program. The Hardy-Weinberg equilibrium and differences in genotype frequencies were tested using a chi-square test. Differences were considered significant at p